Legal and U.S. Regulatory Proceedings (Details Textual) $ in Thousands		12 Months Ended
	Oct. 20, 2017 drugs	Dec. 31, 2017 USD ($) lawsuit generic_manufacturer_defendants drugs	Dec. 31, 2016 USD ($)
Legal and U.S. Regulatory Proceedings Details [Line Items]
Accrued costs for clean-up and remediation | $		$ 118
Restricted cash included in other assets | $		$ 120	$ 122
Settlement terms		On December 4, 2015, Galderma Laboratories, L.P. and Galderma S.A. (collectively, “Galderma”) filed a complaint in the United States District Court for the Northern District of Texas against the Company alleging infringement of United States Patent No. 6,106,848 based upon the Company’s submission to the FDA of an ANDA seeking FDA approval to market clobetasol propionate lotion 0.05% before the expiration patent asserted in the complaint.
Estimated Clean Up Costs
Legal and U.S. Regulatory Proceedings Details [Line Items]
Cost for clean-up and remediation | $		$ 889
Anti-Trust Lawsuit
Legal and U.S. Regulatory Proceedings Details [Line Items]
Number of actions | lawsuit		12
Number of defendants | generic_manufacturer_defendants		35
Number of drugs involved | drugs		29
Stayma Consulting Services [Member]
Legal and U.S. Regulatory Proceedings Details [Line Items]
Number of drugs involved | drugs	2
Damages sought | $		$ 1,700
Opt Out | Anti-Trust Lawsuit
Legal and U.S. Regulatory Proceedings Details [Line Items]
Number of actions | lawsuit		1
Number of defendants | lawsuit		36
Number of drugs involved | lawsuit		30